Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNS561 and Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
NCT05874414Phase 2Recruiting
- Sponsor
- Genfit
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ezurpimtrostat in cholangiocarcinoma (CCA), sponsored by Genfit. Started Aug 2023; status: recruiting.
02
Drugs
ezurpimtrostat
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05874414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874414.